Program overview
Context
Indication: Triple Negative Breast Cancer (TNBC)
Mechanism: Unknown
Modality: Unknown
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Low Signal
Sacituzumab Tirumotecan plus Tagitanlimab
Sacituzumab Tirumotecan plus Tagitanlimab is flagged as low signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 0/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 1/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT07153965
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT07153965 | Low Signal (NOT_YET_RECRUITING) | None | Low Signal | rare_population_signal | strict_eligibility_signal |